CFRXQ — CONTRAFECT Share Price
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$5.41m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase, is used for the treatment of methicillin-resistant S. aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients. Its exebacase is being studied in an ongoing Phase Ib/II study in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci. Its other product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumanni, and has demonstrated potent in vivo activity against these pathogens.
Directors
- Roger Pomerantz CHM (64)
- Steven Gilman VCH (68)
- Michael Messinger CFO (46)
- Cara Cassino EVP (59)
- Gary Woodnutt SVP
- Natalie Bogdanos GCN (52)
- Sol Barer LED (73)
- Lishan Aklog IND (55)
- Jane Barlow IND (61)
- David Low IND (62)
- Michael Otto IND (72)
- Cary Sucoff IND (69)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- March 5th, 2008
- Public Since
- July 29th, 2014
- No. of Shareholders
- 71
- No. of Employees
- 23
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 10,704,803
- Address
- 28 Wells Avenue, 3rd Floor, YONKERS, 10701
- Web
- Phone
- +1 9142072300
- Auditors
- Ernst & Young LLP
Upcoming Events for CFRXQ
Similar to CFRXQ
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the CONTRAFECT share price?
As of Today at 20:04 UTC, shares in CONTRAFECT are trading at $0.00. This share price information is delayed by 15 minutes.
How has the CONTRAFECT share price performed this year?
Shares in CONTRAFECT last closed at $0.00 and the price had moved by -99.43% over the past 365 days. In terms of relative price strength the CONTRAFECT share price has underperformed the S&P500 Index by -99.47% over the past year.
What are the analyst and broker recommendations for CONTRAFECT?
The overall consensus recommendation for CONTRAFECT is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the CONTRAFECT dividend yield?
CONTRAFECT does not currently pay a dividend.
Does CONTRAFECT pay a dividend?
CONTRAFECT does not currently pay a dividend.
When does CONTRAFECT next pay dividends?
CONTRAFECT does not currently pay a dividend.
How do I buy CONTRAFECT shares?
To buy shares in CONTRAFECT you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of CONTRAFECT?
As of the previous close price of $0.00, shares in CONTRAFECT had a market capitalisation of $0.00m.
Where are CONTRAFECT shares listed?
Here are the trading details for CONTRAFECT:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: CFRXQ
What kind of share is CONTRAFECT?
Based on an overall assessment of its quality, value and momentum CONTRAFECT is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a CONTRAFECT share price forecast for 2025?
The analyst consensus target price for shares in CONTRAFECT is $7.00. That is 6999900% above the last closing price of $0.00.
Analysts covering CONTRAFECT currently have a consensus Earnings Per Share (EPS) forecast of -$3.44 for the next financial year.
Find out moreWhat is the trend in the CONTRAFECT share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CONTRAFECT. Over the past six months, its share price has outperformed the S&P500 Index by +9926.53%.
As of the last closing price of $0.00, shares in CONTRAFECT were trading -99.3% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the CONTRAFECT PE Ratio?
The CONTRAFECT PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of CONTRAFECT?
CONTRAFECT's management team is headed by:
- Roger Pomerantz - CHM
- Steven Gilman - VCH
- Michael Messinger - CFO
- Cara Cassino - EVP
- Gary Woodnutt - SVP
- Natalie Bogdanos - GCN
- Sol Barer - LED
- Lishan Aklog - IND
- Jane Barlow - IND
- David Low - IND
- Michael Otto - IND
- Cary Sucoff - IND